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The upper respiratory tract mucosa represents the first line of defense, which has to be overcome by pathogens
before invading the host. Considering the economic and ethical aspects involved in using experimental animals for
pathogenesis studies, respiratory mucosal explants, in which the tissue’s three-dimensional architecture is preserved,
may be ideal alternatives. Different respiratory mucosal explant cultures have been developed. However, none of
them could be inoculated with pathogens solely at the epithelium side. In the present study, equine nasal and
nasopharyngeal explants were embedded in agarose (3%), leaving the epithelium side exposed to allow apical
inoculation. Morphometric analysis did not show degenerative changes during 72 h of cultivation. The number of
apoptotic cells in the mucosa slightly increased over time. After validation, the system was used for apical infection
with a European strain (08P178) of equine arteritis virus (EAV) (107.6TCID50/mL per explant). Impermeability of
agarose to virus particles was demonstrated by the absence of labeled microspheres (40nm) and a lack of
EAV-antigens in RK13 cells seeded underneath the agarose layer in which inoculated explants were embedded.
At 72 hpi, 27% of the EAV-positive cells were CD172a+ and 19% were CD3+ in nasal explants and 45% of the
EAV-positive cells were CD172a+ and 15% were CD3+ in nasopharyngeal explants. Only a small percentage of
EAV-positive cells were IgM+. This study validates the usefulness of a polarized mucosal explant system and shows
that CD172a+ myeloid cells and CD3+ T lymphocytes represent important EAV-target cells in the respiratory
mucosa.Introduction
The respiratory mucosa consists of the epithelium and
the underlying connective tissue or lamina propria that
are separated by a firm barrier, the basement membrane
(BM). It lines the respiratory tract, including the nasal
cavity, the nasopharynx, the larynx, the trachea and the
bronchial tree and represents the first line of defense
against respiratory infections. However, several patho-
gens, including equine arteritis virus (EAV) [1], use the
respiratory tract as a portal of entry to invade the host.
At the level of the respiratory mucosa, the mechanisms
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reproduction in any medium, provided the orare largely unknown. In vivo experiments are difficult
to perform due to their costs and ethical constraints.
Recently, Glorieux et al., Vandekerckhove et al., and
Steukers et al. developed ex vivo explant models using
gauzes to cultivate respiratory mucosae of pigs [2],
horses [3] and cattle [4], respectively. These models were
successfully used to get better insight into the invasion
mechanisms of alphaherpesviruses [5]. However, the im-
possibility to inoculate the mucosa solely at the epithelial
side was a limitation. In fact, inoculation of equine ex-
plants cultivated on gauzes with pseudorabies virus
(PRV) resulted in infection of endothelial cells while the
epithelium above them was unaffected [6]. Therefore,
the author concluded that infection occurred via the side
regions of the explants [6]. In line with this, when
equine explants cultivated on gauzes are experimentallyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity of infected cells are localized in the connective tissue
mainly at the bottom and lateral sides of the explants. In
an in vivo situation, viruses have to overcome the epithe-
lial layer before invading the host. In the explant system
using only gauzes, all sides of the mucosal explants be-
come exposed to the virus and this barrier phenomenon
is, therefore, lost. As a consequence, early pathogenic
events of certain respiratory agents, such as EAV, may be
quite different in these ex vivo models compared to those
in the in vivo situation. Therefore, it was necessary to cre-
ate a model where the virus could only be delivered at the
apical side. The present study describes a polarized agar-
ose embedded explant model which allows cultivation of
equine nasal and nasopharyngeal mucosae in a semi-
closed system where only the epithelium side of the ex-
plant is exposed to virus upon inoculation. Agarose is a
linear galactose polymer obtained by purification of agar
[7] and it is frequently used as an alternative to agar in
viral plaque assays [8] and microbiological investigations
[9]. In the present study, agarose embedded respiratory
mucosal explants were tested for morphometric integrity
and cell viability. Additionally, this polarized ex vivo model
was used to investigate EAV replication sites and to iden-
tify the mucosal target cells.
Material and methods
Collection of nasal and nasopharyngeal mucosae and
preparation of agarose embedded explant cultures
Nasal septum, nasopharynx and blood from seven horses
of both genders and different ages (3-6 years old) were
collected at the slaughterhouse as previously described
[3]. The collected tissues were immediately transported
to the laboratory in transport medium: phosphate buff-
ered saline (PBS) supplemented with 10 μg/mL gentami-
cin (Invitrogen, Ghent, Belgium), 1 mg/mL streptomycin
(Certa, Braine l’Alleud, Belgium), 1 mg/mL kanamycin
(Sigma, Bornem, Belgium), 1000U/mL penicillin (Con-
tinental Pharma, Puurs, Belgium) and 5 μg/mL fun-
gizone (Bristol-Myers Squibb, New York, USA). The
mucosae were stripped from the underlying layers and
divided into equal fractions of 2 cm2. The nasal explants
were cultured on gauzes for 24 h in 50% D-MEM
(Invitrogen)/50% F12 (Invitrogen) serum-free medium
supplemented with 1 μg/mL gentamicin, 0.1 mg/mL
streptomycin and 100U/mL penicillin. The nasopharyn-
geal explants were cultured on gauzes for 24 h in 50%
D-MEM/50% RPMI (Invitrogen) serum-free medium
supplemented with 1nM Ca++, 1 μg/mL gentamicin, 0.1
mg/mL streptomycin and 100U/mL penicillin.
Six-well culture dishes were pre-seeded with rabbit kid-
ney cells (RK13) and incubated at 37°C in the presence of
5% CO2 until confluency was reached. Afterwards, RK13
medium was replaced with 3 mL of a solution containing50% of sterile 3% agarose (low temperature gelling; Sigma)
and 50% of 2X medium (50% 2X D-MEM/50% 2X
F12 supplemented with 2 μg/mL gentamicin, 0.2 mg/mL
streptomycin and 200U/mL penicillin for nasal explants;
50% 2X D-MEM/50% 2X RPMI supplemented with 2nM
Ca++, 2 μg/mL gentamicin, 0.2 mg/mL streptomycin and
200U/mL penicillin for nasopharyngeal explants). Once
the agarose layer solidified, 1.5 cm2 of stripped mucosa
was placed on top of it with the epithelium upwards.
Additional agarose was added until the lateral surfaces of
the mucosa were fully occluded. Finally, to avoid drying
out during incubation (37°C and 5% CO2), the nasal and
nasopharyngeal mucosae were covered with a tiny film of
nasal or nasopharyngeal serum-free medium, respectively.
Nasal and nasopharyngeal mucosae collected from three
horses were used to examine the structural integrity and
viability of the agarose embedded explants. Upper respira-
tory mucosae of the remaining four animals were included
to investigate the replication and to identify the target cells
of EAV 08P178 in the agarose embedded explants. To
exclude previous EAV infection of the donor animals,
blood samples collected at the slaughterhouse were tested
for EAV specific antibodies by means of a complement-
dependent virus neutralization (VN) test and an im-
munoperoxidase monolayer assay (IPMA) as previously
described [1]. Further, to exclude recent EAV infection,
20% suspensions of nasal and nasopharyngeal mucosae
were processed for virus titration on RK13 cells, immedi-
ately after collection at the slaughterhouse.
Morphometric analysis
At 0, 24, 48 and 72 h of cultivation, nasal and nasopha-
ryngeal explants were fixed in phosphate buffered 3.5%
formaldehyde solution for 24 h. After fixation, the tis-
sues were further processed with an automated system
(Shandon Citadel Tissue Processor, 420 D) and embed-
ded in paraffin. Afterwards, haematoxylin-eosin (HE), re-
ticulin and Van Gieson stainings were performed. At
each time point, the effect of ex vivo cultivation on the
mucosa architecture was evaluated in five randomly se-
lected fields. The structure and thickness of the epithe-
lium were analyzed in the HE stained sections. The
thickness and the continuity of the basement membrane
were evaluated in the reticulin stained sections. The
relative amounts of collagen and nuclei were calculated
in a defined region of interest from five randomly
chosen fields in the Van Gieson stained sections. All
measurements and calculations were performed using
the Cell F Software linked to a BX61 light microscope
(Olympus Optical Co., Hamburg, Germany).
Evaluation of cell viability
The effect of ex vivo cultivation on cell viability was
evaluated using an in-situ cell death detection kit (Roche
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terminal deoxynucleotidyl transferase mediated dUTP
nick end labeling (TUNEL). The TUNEL test was
performed according to the manufacturer’s guidelines on
cryosections preserved in methocelW (Sigma). In both
epithelium and connective tissues, the percentage of
TUNEL-positive cells was assessed in five randomly
chosen fields of 100 cells each.
Validation of the impermeability of agarose to virus
particles
To confirm the agarose impermeability to virus particles,
a preliminary experiment with fluorescent microspheres
was performed. Briefly, a dual-chamber system was cre-
ated by placing a transwell insert (pore size 0.4 μm, 12
mm of diameter; Millipore corporation, Bedford, MA,
USA) filled with 3 mL of 50% agarose (3%) and 50% 2X
medium into a culture dish of a six-well plate. Three mL
of PBS were added to the bottom compartment. One
mL of PBS containing 107.6 streptavidin-labeled micro-
spheres (40nm) (Invitrogen) with slightly smaller dimen-
sions compared to EAV particles (50-100nm) [10] was
brought to the upper compartment, on top of the agar-
ose layer. Zero, 1, 12, 48, 72 and 96 h later, 50 μL of
fluid was collected from both the upper and the bottom
compartments and analyzed with a fluoroskan ascent FL
(Thermo lab system, Altrincham, GB, UK).
To verify that the virus did not cross the agarose layer
during the experimental inoculation, wells used to cul-
ture agarose embedded EAV-inoculated explants were
pre-seeded with RK13 cells. After collection of the ex-
plants, the agarose layer was gently removed from the
wells and the underlying RK13 monolayer was washed,
air dried and submitted for indirect immunohistochem-
istry (IHC). Briefly, the monolayers were fixed with 4%
paraformaldehyde for 10 min at room temperature,
washed twice with PBS and further incubated with
methanol supplemented with 0.1% H2O2. The mono-
layers were subsequently incubated for 1 h with mouse
monoclonal antibody (mAb) 17D3 (1:100), specific for
the nucleocapsid (N) protein of EAV (VMRD, Pullman,
USA) and with a peroxidase-labeled goat anti-mouse
IgG immunoglobulin (Molecular Probes, Oregon, USA)
(1:500). Viral antigen-positive RK13 cells were visualized
with 0.05M of 3-amino-9-ethylcarbazole in acetate buffer
(pH5) supplemented with 0.05% H2O2 and detected by
light microscopy (Olympus Optical Co.).
Virus inoculation
After validation of the agarose embedded explant sys-
tem, the model was used to investigate EAV replication
and to identify the target cells. Nasal and nasopharyn-
geal agarose embedded mucosal explants of three horses
were inoculated with 1 mL of medium containing 107.650% endpoint tissue culture infectious dose (TCID50) of
a European respiratory strain of EAV (isolated in
Belgium, designated 08P178, 4th passage on RK13 cells)
[GenBank: JN25761], [1]. The agarose embedded ex-
plants of a fourth animal were mock-inoculated with 1
mL of medium. After 1 h of incubation at 37°C and 5%
CO2, the inoculum was removed, the explants were
gently washed twice and further incubated with fresh
medium. At 0, 24, 48 and 72 hpi, specimens were col-
lected for quantification and identification of EAV
infected cells by double immunofluorescence stainings
(IF).Identification of EAV infected cells
To quantify and identify individual EAV-positive cells, a
double immunofluorescence staining was performed. For
each donor animal and at each collection time, sixty 8
μm-thick cryosections of nasal mucosa and sixty 8 μm-
thick cryosections of nasopharyngeal mucosa were cut
and fixed in methanol at −20°C for 20 min. For each tis-
sue, twenty cryosections were stained for each cell surface
marker separately. In the first step, optimal dilutions of
mAb DH59B (VMRD), UC F6G-3 (California University,
Davis, USA) or 1.9/3.2 (VMRD) were used as markers
for CD172a+ cells (monocyte lineage), CD3+ cells (pan T
lymphocytes) and IgM+ cells (B lymphocytes), respective-
ly. Afterwards, slides were incubated with Texas RedW-
labeled goat anti-mouse IgG antibodies (Molecular
Probes). In the second step, EAV nucleocapsid (N) protein
was visualized with mAb 17D3 (VMRD), directly labeled
with ZenonW Alexa FluorW 488 Mouse IgG1 Labeling Kit,
according to the manufacturer’s instructions. As a negative
control, sections of the mock-inoculated nasal mucosa
were stained following the aforementioned protocol. In
addition, ten extra sections of inoculated nasal mucosa
were incubated with CD172a+ as primary antibody and
Texas RedW-labeled goat anti-mouse IgG antibodies as
secondary antibody. In a second step, the glass was further
incubated with an irrelevant IgG1 directly labeled with
ZenonW Alexa FluorW 488 Mouse IgG1 Labeling Kit. All
antibodies were diluted in PBS and incubated for 1 h at
37°C. The nuclei were counterstained with Hoechst 33342
(Molecular Probes) for 10 min followed by a further fix-
ation step of 5 min with 4% paraformaldehyde. The num-
ber of viral-antigen positive cells was determined in an
area of 8 mm2 for each nasal and nasopharyngeal mu-
cosae. Further, at each time point, the percentage of
double positive cells (EAV-surface marker+) was calculated
on the total amount of EAV-positive cells counted in the
20 sections stained for that specific cell marker. The
samples were analyzed with a confocal microscope (Leica
TCS SP2 Laser scanning spectral confocal system, Leica
microsystems GmbH, Wetzlar, Germany).
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Morphometric parameters and viability were analyzed
using Prism software to evaluate the variance (ANOVA).
The data are presented as means ± standard deviation of
triple independent experiments. The results were con-
sidered to be significantly different when p < 0.05.
Results
Morphometry
In both nasal and nasopharyngeal mucosal explants,
the architecture of the epithelium (Figure 1a), and the
continuity of the basement membrane (Figure 2a) were
preserved throughout the entire experiment. The
thickness of the epithelium and the basement mem-
brane did not significantly change over time (Figures 1b
and 2b, respectively).
In both nasal and nasopharyngeal mucosae, the rela-
tive amounts of nuclei (Figures 3a, 3b) and collagen
(Figures 3a and 3c) were conserved over time.
Viability
The effect of ex vivo culture on explant viability is given
in Table 1. The nasal and nasopharyngeal mucosal ex-
plants show a slight, not statistically significant, increase
in the number of apoptotic epithelial and stromal cells
at 72 h of cultivation.
Ability of agarose to restrain virus particles
The bead assay, as specified in the material and me-
thods, indicates the ability of agarose to restrain virus
particles. None of the samples collected from the bot-
tom compartment of the dual-chamber system contain-Figure 1 Evaluation of the continuity (a) and the thickness (b) of nasa
remained intact during the entire experiment (72 h). The thickness (indicat
over time. Data are represented as means ± S.D. of triplicate independented streptavidin-labeled microspheres at any time point.
Microspheres remained present in the fluid collected
from the upper compartment up to 96 hpi. In the ab-
sence of agarose, microspheres were readily observed in
the lower compartment.
In addition, IHC staining performed on the RK13
monolayer seeded underneath the EAV-inoculated agar-
ose embedded explants did not reveal EAV-positive cells
at any time point.
Quantification and identification of EAV-antigen positive
cells in agarose embedded explants
Samples included as negative control did not show
EAV-positive cells at any time point. The number of
EAV-positive cells increased in time with a mean of 68
in 8 mm2 of nasal mucosa and 225 in 8 mm2 of naso-
pharyngeal mucosa at 72 hpi. In particular, 54, 74 and
76 antigen-positive cells/8 mm2 were counted in nasal
explants (Figure 4a) and 201, 220 and 254 EAV-positive
cells/8 mm2 were quantified in nasopharyngeal explants
(Figure 4b) of horse 1, 2 and 3, respectively. Specifically,
in nasal mucosa, 22, 34 and 27% of EAV-positive cells
were identified as CD172a+ at 24, 48 and 72 hpi, re-
spectively. The percentage of EAV infected cells positive
for CD3 increased linearly from 10 (24 hpi) to 19% (48
and 72 hpi) during the experiment (Figure 5a). In the
nasopharyngeal mucosal explants, the percentage of
EAV infected cells positive for CD172a increased from
22 (24 hpi) to 26 (48 hpi) and 45% (72 hpi) over time,
while the percentage of EAV infected CD3 cells reached
22% at 24hpi and decreased to 15% afterwards (48 and
72 hpi) (Figure 5b). At 24 hpi, EAV-positive cells werel and nasopharyngeal epithelium (HE-staining). The epithelial layer
ed by arrow) of the epithelial layer did not show significant differences
experiments.
Figure 2 Evaluation of the continuity (a) and the thickness (b) of nasal and nasopharyngeal basement membrane (reticulin-staining).
The collagen type III reticular fiber layer of the basement membrane (lamina reticularis) (indicated by arrows) remained continuous during the
entire experiment (72 h). No significant differences in the thickness of the basement membrane were found at any time point. Data represent
means ± S.D. of triplicate independent experiments.
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nasopharyngeal mucosae and, at later time points
(48 and 72 hpi), were scattered all over the connec-
tive tissue. In general, individual EAV-infected cells
were mostly found under the basement membrane with
a sporadic presence in between epithelial cells. In
addition, in nasopharyngeal explants individual EAV-Figure 3 Percentage of cells (a-b) and collagen (a-c) in nasal and naso
colors to collagen and nuclei (setting a threshold), relative amounts of colla
light microscopy. No significant differences in the percentage of cells and c
triplicate independent experiments.positive cells were frequently localized in the para-
follicular area. Viral antigen-positive cells were not
found at the cutting edges of the agarose embedded
explants. Intracellularly, viral antigens were seen in
the cytoplasm (Figure 6), in the form of small dots
(Figure 6a) but mostly in the form of large masses oc-
cupying most of the cytoplasm (Figures 6b and c).pharyngeal mucosae (Van Gieson-staining). By giving different
gen and nuclei were measured during cultivation (72 h) by means of
ollagen were found at any time point. Data represent means ± S.D. of
Table 1 Percentage of TUNEL-positive cells in the epithelium and underlying connective tissue.
Percentage of TUNEL-positive cells at. . .h of cultivation
0 24 48 72
Nasal mucosa epithelium 0.2 ± 0.4 0.6 ± 0.6 0.4 ± 0.2 0.4 ± 0.8
lamina propria 0.8 ± 0.7 1.3 ± 1.0 3.0 ± 0.7 4.9 ± 2.7
Nasopharyngeal mucosa epithelium 0.4 ± 0.3 0.8 ± 1.0 0.7 ± 1.3 0.7 ± 0.5
lamina propria 0.5 ± 0.8 1.7 ± 1.8 3.0 ± 0.4 5.5 ± 1.9
Percentage of TUNEL-positive cells was used as a parameter to determine the effect of in vitro culture on the viability of equine nasal and nasopharyngeal
agarose embedded mucosal explants. No significant differences in the occurrence of apoptosis were found at any time point. Data are represented as means ± S.
D. of triplicate independent experiments.
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The mucosa of the upper respiratory tract (URT) repre-
sents the first line of defense against respiratory patho-
gens but often also serves as a portal of entry for several
microorganisms, whether or not causing generalized in-
fection. The principal viral agents responsible for re-
spiratory disorders in horses are equine herpesvirus-1
(EHV-1) and equine herpesvirus-4 (EHV-4) [11], equine0
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animal and at each collection time, sixty 8 μm-thick cryosections of nasal m
were cut and fixed in methanol. EAV nucleocapsid (N) protein was visualize
Mouse IgG1 Labeling Kit, according to the manufacturer’s instructions. The
viral-antigen positive cells was determined in an area of 8 mm2 for each na
increased in time with a mean of 68 in 8 mm2 of nasal mucosa and 225 in
76 antigen-positive cells/8 mm2 were counted in nasal explants and 201, 2
nasopharyngeal explants of horse 1, 2 and 3, respectively.arteritis virus (EAV) [12] and equine influenza virus
[13]. A previous system used by Vandekerckhove et al.
allowed cultivating four representative tissues of the
equine URT up to 96 h without significant changes in
morphology and viability [3]. In that model, the explants
were cultivated on gauzes allowing nutrients to pene-
trate through all sides of the mucosa. Because of the
small size of the explants (0.5 cm2, few mm thick) and0
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Figure 5 Identification of EAV-positive leukocytes in agarose embedded nasal (a) and nasopharyngeal (b) explants. Lines show the
means ± S.D. of triplicate independent experiments.
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parts of the tissues. In this system, pathogens, just like
nutrients, do not only enter the mucosa at the upper
epithelium side, but also at the edges through the open
spaces of the connective tissue. In fact, inoculation of
such explant systems with PRV [6] or EAV 08P178 (our
own studies, not published) resulted in an extensive
spread of the virus, mainly at the bottom and lateral
sides of the mucosal explants. Therefore, in order to bet-
ter mimic the in vivo situation, we established a new
model in which, through agarose embedded explants, a
polarized system was obtained so that pathogens couldFigure 6 Representative confocal photomicrographs illustrating viral
positive cells can be distinguished: big cells with a big round or oval nucle
and rather small cells with a big round or oval nucleus surrounded by a sm
could be found in the form of small dots (a) or in the form of large masseonly enter through the upper epithelium. The results of
morphometric analysis of the epithelium, basement
membrane and connective tissue and of TUNEL assays
demonstrate that the agarose system allows cultivating
explants up to 72 h without substantial alterations in the
morphology and the viability of the tissues. Further, an
assay based on streptavidin-labeled microspheres to-
gether with the absence of EAV-antigens in RK13 cells
seeded underneath the agarose layer in which inoculated
explants were embedded and the lack of viral antigen-
positive cells at the cutting edges of the agarose em-
bedded explants, demonstrate that the access of thetropism for leukocyte subpopulations. Two different types of EAV-
us surrounded by large cytoplasmic extensions mostly CD172a+ (a)
all rim of cytoplasm mostly CD3+ or IgM+ (b-c). The viral antigens
s occupying most of the cytoplasm (b-c). Scale bar represents 10 μm.
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of the epithelium.
We recently showed that, upon in vivo oro-nasal inocu-
lation, EAV 08P178 starts its replication in nasal and naso-
pharyngeal regions and lungs [1]. Therefore, to gain more
insight into the early phase of EAV respiratory infection,
kinetic studies were performed by inoculating the agarose
embedded nasal and nasopharyngeal mucosal explants
with EAV 08P178. Currently, little is known about the
early phases of EAV pathogenesis such as (i) which strat-
egy EAV uses to invade the host, (ii) what are the first cells
to be infected at the entry site or (iii) how blood vessels
are reached to disseminate the virus throughout the body.
The current study showed that in the explant model, the
majority of EAV-positive cells were CD172a+ myeloid cells
followed by CD3+ T-lymphocytes, whereas only a small
percentage were IgM+ B-lymphocytes. Previously, we
speculated that, at the level of the URT, EAV hijacks
mononuclear leukocytes to penetrate the BM and evade
the immune response [1]. In possible support of this, the
present study shows a high percentage of EAV-infected
CD172a+ cells. CD172a was expressed on equine mono-
cytes, macrophages, dendritic cells (DC) and granulocytes.
DC have specific characteristics: (i) they have a major role
in activating naïve and resting antigen-specific T cells [14],
(ii) they are migratory cells, unlike differentiated macro-
phages [15] and (iii) they are abundantly present within
the airway epithelium [16] forming a network of antigen
presenting cells in the respiratory mucosa [17,18]. DC play
a central role in initiating an immune response against
infecting agents [19] but may also contribute to the patho-
genesis and the spreading of several respiratory pathogens
as shown for human [20] and simian [21] immunodefi-
ciency viruses, cytomegalovirus [22] and Mycobacterium
tuberculosis [23]. Hence, it is tempting to speculate that
DC could play an important role in the early phases of
EAV pathogenesis. This theory could corroborate the find-
ings of Del Piero that described EAV-antigens within stro-
mal dendrite-like cells of lymph node sinuses and spleen
[12]. On the contrary, since the main function of myeloid
cells is to capture antigens, CD172a+ cells may be positive
for the EAV nucleocapsid protein due to phagocytosis ra-
ther than infection.
It is generally believed that EAV has a tropism main-
ly for the monocyte/macrophage population. However,
Castillo-Olivares et al. showed that EAV-infected PBMC
are negative for the human monocyte/granulocyte mar-
ker L1 (calprotectin) [24]. In the present study, both
T-lymphocytes and cells of the monocyte/macrophage
lineage were found to be infected with EAV. Other stud-
ies have also demonstrated that EAV can infect CD3+ T
lymphocytes in PBMC in vitro [25,26].
In the present study, 37 to 64% of EAV-positive cells
were identified. Since EAV has a wide tropism [27], thepercentage of non-identified EAV-positive cells may be
epithelial cells, endothelial cells, mesenchymal stromal
cells, and natural killer cells. In fact, in vivo, EAV-
antigens were demonstrated within the cytoplasm of
endothelial cells, myometrial and cardiac myocytes,
chorionic mesenchymal stromal cells and epithelial cells
such as alveolar pneumocytes, enterocytes, adrenal cor-
tical cells, trophoblast, thymus stroma, and renal tubular
cells [27]. Therefore, it will be interesting to further
identify the remaining EAV-positive cells in future ex-
periments using the agarose explant system.
Although polarized mucosal explants are much more
physiological than non-polarized ones and in vitro cell
cultures, they are only suitable to study the early stages
of the pathogenesis of viruses that use the respiratory
tract as a portal of entry. It must be kept in mind that
the mucosal explants not fully represent the whole scope
of virus-animal interactions since the inflammatory pro-
cesses including invasion of blood elements are absent.
However, preliminary results obtained with nasal mu-
cosa from experimentally EAV-inoculated ponies were
very similar to those of the present in vitro study,
confirming the relevance of the polarized mucosal ex-
plant system. In conclusion, the present study demon-
strates that the agarose embedded explant model
represents a valid tool to study some aspects of the early
steps in the pathogenesis of equine respiratory viruses
such as EAV and that mucosal CD172a+ myeloid cells
and CD3+ T lymphocytes represent important target
cells for EAV.
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